NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “Monoclonal antibodies provided benefits to vulnerable populations and six different ones were authorized to treat COVID-19,” said Dr. Wayne Winegarden, ...
NEW BRIEF: End Anti-Market Distortions in Current PBM System Would Lower Patient Costs, Increase Access to Life-Saving Drugs
SACRAMENTO – Fixing the current broken system that incentivizes pharmacy benefit managers (PBMs) to enact policies that benefit themselves and insurers at the expense of patients would lead to lower patient drug costs, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “The current system incentivizes PBMs to implement policies that benefit insurers and themselves, while making drugs less ...
Oh, Canada: U.S. Patients Don’t Want Your Health Policies
There’s never been a worse time to get sick in Canada. Our northern neighbors must wait 2.5 years longer than Americans enrolled in Medicare to access new drugs, according to a report published this month by the Canadian Health Policy Institute. The Canadian government has chosen to deprive its citizens of the latest therapies by dictating the prices drug makers must abide by if they want access to the Canadian market. And now, the Biden administration and ...
Trending Topics
Studies
